Cartesian Therapeutics (RNAC) Enterprise Value (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Enterprise Value data on file, last reported at -$1.7 million in Q1 2026.

• On a quarterly basis, Enterprise Value rose 99.06% year-over-year to -$1.7 million in Q1 2026; TTM through Mar 2026 was -$1.7 million, a 99.06% increase from a year earlier, with the FY2025 full-year figure at -$125.1 million, up 41.14% from the prior year.
• Enterprise Value for Q1 2026 stood at -$1.7 million, up from -$125.1 million in the prior quarter.
• Over the last five years, Enterprise Value for RNAC reached as high as -$1.7 million in Q2 2025 and fell as low as -$219.2 million in Q3 2024.
• Historically, Enterprise Value has averaged -$109.9 million across 5 years, with a median of -$117.4 million in 2022.
• Across the five-year window, Enterprise Value slumped 176.44% in 2024 and surged 99.22% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$134.6 million in 2022, then soared by 42.86% to -$76.9 million in 2023, then plunged by 176.44% to -$212.6 million in 2024, then surged by 41.14% to -$125.1 million in 2025, then jumped by 98.64% to -$1.7 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$1.7 million in Q1 2026, -$125.1 million in Q4 2025, and -$1.7 million in Q3 2025.